For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
After finishing at $2.55 in the prior trading day, Pyxis Oncology Inc (NASDAQ: PYXS) closed at $2.91, up 14.12%. In other words, the price has increased by $14.12 from its previous closing price. On the day, 0.85 million shares were traded. PYXS stock price reached its highest trading level at $2.91 during the session, while it also had its lowest trading level at $2.56.
Ratios:
Our goal is to gain a better understanding of PYXS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.65 and its Current Ratio is at 5.65. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.20.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Guggenheim on September 04, 2025, initiated with a Buy rating and assigned the stock a target price of $5.
On November 08, 2024, Stephens started tracking the stock assigning a Overweight rating and target price of $13.Stephens initiated its Overweight rating on November 08, 2024, with a $13 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 21 ’25 when HUMPHREY RACHEL bought 13,896 shares for $1.03 per share.
HUMPHREY RACHEL bought 200 shares of PYXS for $194 on Apr 17 ’25. On Apr 14 ’25, another insider, HUMPHREY RACHEL, who serves as the Director of the company, bought 1,400 shares for $0.97 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PYXS now has a Market Capitalization of 180472784 and an Enterprise Value of 110990776. For the stock, the TTM Price-to-Sale (P/S) ratio is 64.00 while its Price-to-Book (P/B) ratio in mrq is 2.06. Its current Enterprise Value per Revenue stands at 39.358 whereas that against EBITDA is -1.378.
Stock Price History:
The Beta on a monthly basis for PYXS is 1.33, which has changed by -0.07765454 over the last 52 weeks, in comparison to a change of 0.16845357 over the same period for the S&P500. Over the past 52 weeks, PYXS has reached a high of $5.39, while it has fallen to a 52-week low of $0.83. The 50-Day Moving Average of the stock is 73.81%, while the 200-Day Moving Average is calculated to be 115.68%.
Shares Statistics:
The stock has traded on average 582.94K shares per day over the past 3-months and 600540 shares per day over the last 10 days, according to various share statistics. A total of 62.02M shares are outstanding, with a floating share count of 44.14M. Insiders hold about 28.82% of the company’s shares, while institutions hold 39.19% stake in the company. Shares short for PYXS as of 1757894400 were 4359697 with a Short Ratio of 7.48, compared to 1755216000 on 5032348. Therefore, it implies a Short% of Shares Outstanding of 4359697 and a Short% of Float of 8.51.
Earnings Estimates
. The current market rating for Pyxis Oncology Inc (PYXS) reflects the collective analysis of 7.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.31, with high estimates of -$0.25 and low estimates of -$0.41.
Analysts are recommending an EPS of between -$1.14 and -$1.42 for the fiscal current year, implying an average EPS of -$1.28. EPS for the following year is -$1.17, with 7.0 analysts recommending between -$0.78 and -$1.42.
